Until now, Lumigan (bimatoprost ophthalmic solution) 0.03% was used as a second-line treatment for glaucoma. Now the Allergan once-daily prescription eyedrop has been approved for first-line treatment of elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension.
Eyedrop grows from second- to first-line Rx for glaucoma
Until now, Lumigan (bimatoprost ophthalmic solution) 0.03% was used as a second-line treatment for glaucoma. Now the Allergan once-daily prescription eyedrop has been approved for first-line treatment of elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.